Kura Oncology, Inc.
KURA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001422143
In the last 90 days, Kura Oncology, Inc. insiders filed 2 open-market purchases and 8 sales; 221 institutions reported holding it in 13F filings for Q2 2026, worth $953.1M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $713.9M
- Insider buysLast 90 days, $2.35M in total
- 2
- Insider sellsLast 90 days, $1.71M in total
- 8
- 13F holdersQ2 2026, +2 vs. previous quarter
- 221
- 13F valueReported value at the end of Q2 2026
- $953.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $67.5M
- +25.2% year over year
- Net income, FY2025
- -$278.7M
- No comparable prior period
- Free cash flow, FY2025
- -$70.7M
- −152.8% year over year
- Revenue, Q3 FY2026
- $22.8M
- +10.1% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $278.7M (412.9% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 12.6M
- Shares sold short
- Change
- −1.68M
- −11.7% vs. previous
- Days to cover
- 7.86
- At average daily volume
Superinvestors holding KURA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding KURA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Kura Oncology, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 29, 2026 (view filing)6:30 PM ET | Sep 28 | 1 day | Bair Teresa BrophyChief Legal Officer | SSale | −8.44K | $10.50 | −$88.6K | −4.3%187.0K after | 10b5-1 |
| Sep 29, 2026 (view filing)6:30 PM ET | Sep 28-29 | 1 day | Ford KathleenChief Operating Officer | SSale | −10.6K | $10.59 | −$111.9K | −6.9%143.0K after | 2 lots10b5-1 |
| Sep 29, 2026 (view filing)6:30 PM ET | Sep 28-29 | 1 day | Leoni MollieChief Medical Officer | SSale | −41.3K | $10.67 | −$440.2K | −22.6%141.1K after | 2 lots |
| Sep 29, 2026 (view filing)6:30 PM ET | Sep 28 | 1 day | Doyle Thomas JamesSVP, Finance & Accounting | SSale | −4.61K | $10.50 | −$48.4K | −3.1%142.4K after | |
| Sep 29, 2026 (view filing)6:30 PM ET | Sep 28-29 | 1 day | Powl Brian T.Chief Commercial Officer | SSale | −32.5K | $10.63 | −$345.0K | −19.2%136.8K after | 3 lots |
| Sep 25, 2026 (view filing)4:05 PM ET | Sep 24 | 1 day | Burrows FrancisChief Scientific Officer | SSale | −20.7K | $10.83 | −$224.5K | −32.9%42.3K after | |
| Aug 24, 2026 (view filing)5:30 PM ET | Aug 24 | Same day | Wilson Troy EdwardPresident and CEO | PPurchase | +100.0K | $12.39 | +$1.24M | +26.4%479.2K after | |
| Aug 24, 2026 (view filing)5:30 PM ET | Aug 21 | 3 days | Powl Brian T.Chief Commercial Officer | SSale | −4.34K | $11.89 | −$51.7K | −2.5%169.3K after | 10b5-1 |
| Aug 21, 2026 (view filing)4:30 PM ET | Aug 19 | 2 days | Bair Teresa BrophyChief Legal Officer | SSale | −31.5K | $12.63 | −$397.7K | −13.9%195.4K after | 10b5-1 |
| Aug 17, 2026 (view filing)4:45 PM ET | Aug 17 | Same day | Wilson Troy EdwardPresident and CEO | PPurchase | +100.0K | $11.12 | +$1.11M | +35.8%379.2K after |
Top 10 13F holders, Q2 2026
See all 221 holdersThe largest institutional positions in Kura Oncology, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10,509,233 | $115.3M | 0.00% | +871,702+9.0% | Added |
| Suvretta Capital Management, LLC | 8,575,422 | $94.1M | 1.98% | 00.0% | Unchanged |
| BVF Inc | 8,445,769 | $92.7M | 2.37% | 00.0% | Unchanged |
| State Street Corp | 5,329,208 | $58.5M | 0.00% | +817,317+18.1% | Added |
| Vanguard Capital Management LLC | 3,916,164 | $43.0M | 0.00% | +130,479+3.4% | Added |
| Armistice Capital, LLC | 3,678,000 | $40.3M | 1.12% | −58,000−1.6% | Reduced |
| AQR Capital Management LLC | 3,126,727 | $34.3M | 0.01% | +1,002,247+47.2% | Added |
| Goldman Sachs Group Inc | 2,265,171 | $24.8M | 0.00% | +831,700+58.0% | Added |
| Geode Capital Management, LLC | 2,229,958 | $24.5M | 0.00% | +195,682+9.6% | Added |
| Alethea Capital Management, LLC | 2,167,938 | $23.8M | 9.85% | +638,569+41.8% | Added |
Holders of 5% or more of KURA
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Kura Oncology, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Biotechnology Value Fund L P | 13G/A | 9.99%8.68M shares | +2.49 ppfrom 7.50% | Feb 11, 20218 filings | Nov 14, 2025 | SEC |
| Suvretta Capital Management, LLC | 13G/A | 9.70%8.58M shares | +0.30 ppfrom 9.40% | Dec 9, 20217 filings | Aug 14, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 8.90%7.91M shares | +1.10 ppfrom 7.80% | Jan 8, 20253 filings | Oct 27, 2026 | SEC |
| Armistice Capital, LLC | 13G/A | 7.14%6.20M shares | – | Aug 15, 20251 filing | Aug 15, 2025 | SEC |
| State Street Corp | 13G | 5.70%4.93M shares | – | Feb 11, 20224 filings | Feb 9, 2026 | SEC |
Politician trades
All politician trades in KURA1 member of Congress reported 1 trade in Kura Oncology, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Jan 20, 2023 |  Chris Jacobs House · NY | Buy | $1K-$15K |
House · NY · Jan 20, 2023
Buy$1K-$15K